Lobeglitazone (CKD-501 Chong Kun Dang Pharmaceutical Corp., Seoul, Korea) is a novel PPAR-c agonist with substituted pyrimidine derivatives containing TZD (Data S1)
Thiazolidinediones (TZDs), peroxisome proliferator-activated receptor (PPAR)-c agonists, are the initial drugs that strengthen insulin...